---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-028641"
form_type: "8-K"
ticker: null
cik: "0001610618"
company_name: "Cidara Therapeutics, Inc."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T16:30:58.630706+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CFO Preetam Shah departs; Frank Karbe appointed as new CFO effective Feb 24, 2025

## Summary
- CFO Preetam Shah to separate on Feb 24, 2025; receives 9 months’ salary, 2024 bonus, and 15 months’ COBRA.
- Shah will consult for six months with continued equity vesting during consulting period.
- Frank Karbe named CFO effective Feb 24; previously CEO of Better Therapeutics and CFO of Myovant Sciences.
- Karbe’s base salary $525K, target bonus 40%, signing bonus $50K; options for 115K shares and RSUs for 57.5K shares.
- Severance for Karbe: 9 months’ salary without cause/resignation for good reason; 12 months with change of control.

## SEC filing metadata
- accession: 0001193125-25-028641
- form_type: 8-K
- cik: 0001610618
- company_name: Cidara Therapeutics, Inc.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610618/000119312525028641/0001193125-25-028641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610618/000119312525028641/d928043d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-028641
- JSON: https://secwatch.observer/filing/0001193125-25-028641.json
- Plain text: https://secwatch.observer/filing/0001193125-25-028641.txt

## Key facts
- Executive change
  Frank Karbe was appointed as Chief Financial Officer at Cidara Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On February 14, 2025, the Board appointed Frank Karbe, 56, as the Company’s Chief Financial Officer (including as its principal financial officer and principal accounting officer), effective as of Mr. Karbe’s employment start date, which is expected to be February 24, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610618/000119312525028641/0001193125-25-028641-index.htm
- Executive change
  Preetam Shah resigned as Chief Financial Officer at Cidara Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On February 12, 2025, Cidara Therapeutics, Inc. (the “Company”) and Preetam Shah, Ph.D., MBA., the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, mutually agreed to Dr. Shah’s separation from such roles with the Company, effective February 24, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610618/000119312525028641/0001193125-25-028641-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.